Evidence map›Paper›PMID 42210310›Full record

ReviewMolecular cancer2026

Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape.

Michele Bevere, Anastasios Gkountakos, Silvia Valentinuzzi, Simone De Fabritiis, Chee S Wong, Riccardo De Robertis, Paola Mattiolo, Manuel Gentiluomo, Matteo Fassan, Antonio Pea and 17 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Michele BevereARC-Net Research Centre, University of Verona, Verona, Italy.
Anastasios GkountakosDepartment of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Silvia ValentinuzziDepartment of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Simone De FabritiisCenter for Advanced Studies and Technology (CAST), Chieti, Italy.
Chee S WongQueen Elizabeth University Hospital, Birmingham, UK.
Riccardo De RobertisDepartment of Diagnostics and Public Health, Section of Radiology, University of Verona, Verona, Italy.
Paola MattioloDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Manuel GentiluomoDepartment of Biology, University of Pisa, Pisa, Italy.
Matteo FassanDepartment of Medicine, University of Padua, Padua, Italy.
Antonio PeaUnit of Pancreatic Surgery, Verona University Hospital Trust, Verona, Italy.
Stefano F CrinòDepartment of Medicine, University of Verona, Verona, Italy.
Michele SimboloDepartment of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Andrea MafficiniARC-Net Research Centre, University of Verona, Verona, Italy.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Sara CingarliniDepartment of Medicine, University and Hospital Trust of Verona, Verona, Italy.
Luca LandoniUnit of Pancreatic Surgery, Verona University Hospital Trust, Verona, Italy.
Rita T LawlorARC-Net Research Centre, University of Verona, Verona, Italy.
Roberto SalviaUnit of Pancreatic Surgery, Verona University Hospital Trust, Verona, Italy.
Mirko D'OnofrioDepartment of Diagnostics and Public Health, Section of Radiology, University of Verona, Verona, Italy.
Michele MilellaDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Volkan AdsayDepartment of Pathology, Koç University Hospital and Koç University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.
Lodewijk A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Christopher M HeaphySection of Hematology and Medical Oncology, Boston University and Boston Medical Center, MA, Boston, USA.
Seung-Mo HongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Aatur D SinghiDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Aldo ScarpaARC-Net Research Centre, University of Verona, Verona, Italy. aldo.scarpa@univr.it.
Claudio LuchiniARC-Net Research Centre, University of Verona, Verona, Italy. claudio.luchini@univr.it.

Funding

Fondazione AIRC per la ricerca sul cancro ETS 26343Fondazione AIRC per la ricerca sul cancro ETS 28054; 29829Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona 203885Fondazione Italiana per la ricerca sulle Malattie del Pancreas J38D19000690001
6 · The paper itself

Abstract

Pancreatic neuroendocrine neoplasms (PanNENs) constitute a heterogeneous group of tumors distinguished by substantial variability in morphology, immunophenotype, molecular characteristics, and clinical behavior. In recent years, the advent of multiple omics-based methodologies has significantly enhanced our understanding of these neoplasms. Integrating histology and genomics with survival analyses has clarified that the fundamental distinction within this disease spectrum lies between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Furthermore, genomics, transcriptomics, and epigenetic profiling have deepened the granularity of the PanNET landscape, revealing marked differences even within the same diagnostic category, with important clinical implications. For example, DAXX/ATRX mutations, activation of the alternative lengthening of telomeres pathway, BEND2 gene fusions, and an α-cell transcriptional profile are more frequently associated with adverse outcomes. Additional omics approaches, including metabolomics, proteomics, radiomics, and the more recently developed spatially resolved methodologies, are further expanding current knowledge in this challenging field. In this review, we provide an integrated overview of PanNENs, synthesizing insights generated across diverse multi-omics platforms.

Indexed as

Biomarkers, TumorGenomicsNeuroendocrine TumorsPancreatic NeoplasmsGene Expression ProfilingHumansMetabolomicsMultiomicsProteomicsBiomarkers, TumorGenomicsMetabolomicsNeuroendocrineOmicsPanNECPanNETProteomicsRadiomics.Transcriptomics

Identifiers

PMID42210310
PMCPMC13425959

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.